808钱包APP

Be the most trusted biotech company

2024-12-04

Henlius Receives IND Approval from NMPA for a Phase 1b/2 Clinical Trial of Its Novel PD-L1-Targeting ADC HLX43
2024-12-04

Henlius Receives Approval form NMPA for a Phase 2 Clinical Trial of Its Novel Anti-HER2 mAb HLX22
2024-12-04

China NMPA Accepts Henlius' NDA for HLX11, an Pertuzumab Biosimilar Candidate
2024-12-03

Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of nsNSCLC
2024-11-29

First Shipment of Henlius Trastuzumab to U.S.
2024-11-26

Henlius Recognized as 2024 Forbes China Go-International Series Top 30
2024-11-25

Henlius 2024 Second Scientific Advisory Board Meeting Held
2024-11-22

First Patient Dosed in Phase 3 MRCT of Dual HER2 Blockade Therapy for HER2+ GC
2024-11-20

Cancer Communications Published the Results of HLX07-ESCC201: HLX07 as monotherapy or combination therapy in ESCC